Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.

Meiwei Bioscience (688062.SH) announced that the company has recently received the "Study May Proceed Notification" from the Food and Drug Administration (FDA) of the United States. The clinical trial application for 9MW1911 injection has officially obtained FDA approval. 9MW1911 is an innovative monoclonal antibody developed independently based on an efficient B lymphocyte selection platform. It belongs to the first class of therapeutic biologics and can bind with high affinity to the ST2 receptor, thereby blocking the IL33/ST2 signaling pathway.